Herantis Pharma Plc, Company release, 29 October 2025 at 19:15 pm EET

Composition of Herantis Pharma Plc's Shareholders' Nomination Committee

The following members have been appointed to Herantis Pharma's Shareholders' Nomination Committee:

• Kyösti Kakkonen, representing Joensuun Kauppa ja Kone Oy (Chair),
• Petteri Vaarnanen, representing Säästöpankki Pienyhtiöt and Säästöpankki Kotimaa funds,
• Pia Gisgård, representing Swedbank Robur, and
• Timo Veromaa, the Chair of Herantis Pharma's Board of Directors.

Herantis Pharma's Shareholders' Nomination Committee consists of four members, of which three represent the Company's shareholders. The Chair of Herantis Pharma's Board of Directors will serve as the fourth member of the Nomination Committee.

The Shareholders' Nomination Committee prepares and presents to the Annual General Meeting proposals on the remuneration, number and members of the Board of Directors.

For more information, please contact:

Tone Kvåle, CFO

Tel: +47 915 19576

Email: ir@herantis.com

Certified Advisor:

UB Corporate Finance Ltd

Tel: +358 9 25 380 225

E-mail: ubcf@unitedbankers.fi

About Herantis Pharma Plc

Herantis Pharma Plc is a clinical-stage biotechnology company developing disease-modifying therapies for Parkinson's disease. The Company's lead product, HER-096, is a first-in-class small peptide that combines the neuroprotective mechanism of cerebral dopamine neurotrophic factor (CDNF), with the convenience of subcutaneous administration. In a Phase 1b clinical trial, HER 096 was shown to be generally safe and well tolerated in Parkinson's disease patients. Herantis plans to advance HER-096 into a Phase 2 clinical trial in 2026 to evaluate efficacy, safety and tolerability in early-stage Parkinson's patients.

Herantis is listed on the Nasdaq First North Growth Market Finland.

Company website: www.herantis.com